Dr. Rosenthal, a contributing opinion writer, was an emergency room physician before becoming a journalist.
Earlier in the pandemic it was vital to see doctors over platforms like Zoom or FaceTime when in-person appointments posed risks of coronavirus exposure. Insurers were forced â often for the first time â to reimburse for all sorts of virtual medical visits and generally at the same price as in-person consultations.
By April 2020, one national study found, telemedicine visits already accounted for 13 percent of all medical claims compared with 0.15 percent a year earlier. And Covid hadnât seriously hit much of the country yet. By May, for example, Johns Hopkinsâs neurology department was conducting 95 percent of patient visits virtually. There had been just 10 such visits weekly the year before.
Ultra-high field MRI detects differences in brain s hippocampus eurekalert.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eurekalert.org Daily Mail and Mail on Sunday newspapers.
The US Food and Drug Administration (FDA) has approved ADC Therapeutics’ ZYNLONTA as a third-line therapy for patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL).
The CD19-targeted antibody drug conjugate (ADC) was granted accelerated approval by the US regulator based on overall response rate.
The approval also covers patients with DLBCL arising from low grade lymphoma and high-grade B-cell lymphoma.
“This is the first ever approval of a PBD based ADC,” noted Chris Martin, CEO, ADC Therapeutics, on a conference call about the regulatory development and commercial launch.
The Lausanne, Switzerland based biotech is now entering
FDA Approves Loncastuximab for Diffuse Large B-Cell Lymphomas medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.